CD BioGlyco is specialized in using enzymatic and microbial production technologies for the most advanced and effective production plan of 6’-Galactosyllactose (6’GL).
In recent years, human milk oligosaccharide (HMO) has become an imperative component of infant nutrition food. It has excellent physiological activities such as maintaining the balance of long-regulated bacteria and improving innate immunity, which has attracted the attention of biologists. Among them, 6’GL shows potential and broad market prospects in the infant formula industry and medical industry. It not only exists in human milk but also is isolated from bovine colostrum, caprine milk, camel colostrum, reindeer milk, cheetah milk, and other mammals.
A recent study found that galactooligosaccharides containing 3'-, 4’-, and 6'GL attenuated NF-κB inflammatory signaling in human intestinal epithelial cells and human immature intestines. Therefore, 6'GL has potential clinical research value in reducing inflammation in isolated intestinal tissues.
Another reported study has tested the regulation of human milk oligosaccharides from colostrum on the signal pathway of immature mucosa in vitro, and the analysis identified networks that control the communication of immune cells, differentiation of intestinal mucosal immune system, and homeostasis. It was found that they can reduce the level of inflammatory cytokine protein in the acute phase stimulated by pathogen-related molecular patterns, and elevate the cytokines involved in tissue repair and homeostasis. Among them, 3', 4', and 6'GL play a key role in specific immune regulation: polycytodylic acid-induced IL-8 levels. Therefore, it can be speculated that 6'GL may weaken the response of mucosa to surface inflammatory stimulation at the early stage of development, and enhance the signal supporting the maturation of the intestinal mucosal immune system.
Fig.1 Synthesis of 6’GL. (Hunt, et al., 2022)
CD BioGlyco provides a variety of advanced Production methods, including purification, chemical synthesis, enzyme catalysis, and fermentation to complete the efficient production of 6’GL. The optimization strategies we supply include but are not limited to the following:
Selection and identification of suitable enzymes.
Identification of genes and inhibition or increase of corresponding gene expression.
Construct metabolically engineered strains.
Optimization of strain culture conditions.
Through long-term experiments and research on HMO, CD BioGlyco is at the leading level in the world in the application and improvement of 6’GL synthesis methods. If you need any further information, please feel free to contact us.
Reference
